VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decrease in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 25,097 shares, a drop of 34.6% from the November 30th total of 38,358 shares. Based on an average daily trading volume, of 44,418 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.0% of the company’s shares are short sold. Currently, 1.0% of the company’s shares are short sold. Based on an average daily trading volume, of 44,418 shares, the days-to-cover ratio is currently 0.6 days.

VivoSim Labs Trading Down 3.4%

Shares of VivoSim Labs stock opened at $2.01 on Friday. The stock has a 50-day moving average price of $2.23 and a 200 day moving average price of $2.29. The company has a market cap of $5.25 million, a P/E ratio of -0.46 and a beta of 1.27. VivoSim Labs has a 1 year low of $1.41 and a 1 year high of $21.96.

VivoSim Labs (NASDAQ:VIVS) last released its earnings results on Thursday, November 6th. The company reported ($0.98) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP bought a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent SEC filing. 8.23% of the stock is owned by hedge funds and other institutional investors.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.